HPV Testing by cobas HPV Test in a Population from Catalonia

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lloveras, Belén ^a   Gomez, Silvia ^a   Alameda, Francesc ^a   Bellosillo, Beatriz ^a   Mojal, Sergi ^b   Muset, Mercè ^a   Parra, Manuel ^c   Palomares, José Carlos ^c   Serrano, Sergi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOLOGY; HPV TEST; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASS SCREENING; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SPAIN; STANDARD; STATISTICAL ANALYSIS; UTERINE CERVICITIS; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; SPAIN; UTERINE CERVICAL NEOPLASMS;

EID: 84874638820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058153     Document Type: Article

References (20)

1. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
2. Bouvard V, Baan R, Straif K, Grosse Y, El Ghissassi F, et al. (2009) Special report: Policy. A review of human carcinogens- Part B: biological agents. Lancet Oncol 10: 321-2.
3. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, et al. (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95: 46-52.
4. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-101.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, et al. (2006) New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7: 547-55.
6. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, et al. (2007) Canadian Cervical cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579-88.
7. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754.
8. Meijer CJLM, Berkhof J, Snijders PJF, (2011) A new approach to cervical screening Lancet Oncol. Jul 12(7): 612-3.
9. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras N, et al. (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12 (7): 667-72.
10. Kinney W, Stoler MH, Castle PE, (2010) Patient Safety and the Next Generation of HPV DNA Tests. Am J Clin Pathol 134: 193-9.
11. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, et al. (2006) Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24: S78-S89.
12. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, et al. (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357: 1589-97.
13. Bulkmans N, Berkhof J, Rozendaal L, van Kemenade F, Boeke A, et al. (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet 370: 1764-72.
14. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, et al. (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-20.
15. Heideman DAM, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJG, et al. (2011) Clinical validation of the cobas HPV Test for cervical screening purposes. J Clin Microbiol 49(11): 3983-5.
16. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, et al. (2002) for the Forum Group Members and the Bethesda 2001 Workshop The 2001 Bethesda System Terminology for reporting results of cervical cytology JAMA. 287(16): 2114-19.
17. Schiffman M, Solomon D, (2003) Finding to date from the ASC-US-LSIL Triage Study (ALTS). Arch Pathol Lab Med (127) (): 946-949.
18. Arbyn M, Ronco G, Meijer CJLM, Naucler P, (2009) Trials comparing cytology with human papillomavirus screening. Lancet Oncol 10: 935-6.
19. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, et al. (2011) High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 135: 468-75.
20. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with Human Papillomavirus (HPV) Type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-9.